|
1
|
Weigelt B, Peterse JL and van 't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ripperger T, Gadzicki D, Meindl A and
Schlegelberger B: Breast cancer susceptibility: Current knowledge
and implications for genetic counselling. Eur J Hum Genet.
17:722–731. 2009. View Article : Google Scholar
|
|
3
|
McCubrey JA, Abrams SL, Fitzgerald TL,
Cocco L, Martelli AM, Montalto G, Cervello M, Scalisi A, Candido S,
Libra M, et al: Roles of signaling pathways in drug resistance,
cancer initiating cells and cancer progression and metastasis. Adv
Biol Regul. 57:75–101. 2015. View Article : Google Scholar
|
|
4
|
Kerbel RS, Kobayashi H and Graham CH:
Intrinsic or acquired drug resistance and metastasis: Are they
linked phenotypes? J Cell Biochem. 56:37–47. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lønning PE: Molecular basis for therapy
resistance. Mol Oncol. 4:284–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Munoz M, Henderson M, Haber M and Norris
M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
IUBMB Life. 59:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deeley RG, Westlake C and Cole SP:
Transmembrane transport of endo- and xenobiotics by mammalian
ATP-binding cassette multidrug resistance proteins. Physiol Rev.
86:849–899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nooter K, de la Riviere GB, Klijn J,
Stoter G and Foekens J: Multidrug resistance protein in recurrent
breast cancer. Lancet. 349:1885–1886. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berger W, Setinek U, Hollaus P, Zidek T,
Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M:
Multidrug resistance markers P-glycoprotein, multidrug resistance
protein 1, and lung resistance protein in non-small cell lung
cancer: Prognostic implications. J Cancer Res Clin Oncol.
131:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bagnoli M, Beretta GL, Gatti L, Pilotti S,
Alberti P, Tarantino E, Barbareschi M, Canevari S, Mezzanzanica D
and Perego P: Clinicopathological impact of ABCC1/MRP1 and
ABCC4/MRP4 in epithelial ovarian carcinoma. BioMed Res Int.
2013:1432022013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larbcharoensub N, Leopairat J, Sirachainan
E, Narkwong L, Bhongmakapat T, Rasmeepaisarn K and Janvilisri T:
Association between multidrug resistance-associated protein 1 and
poor prognosis in patients with nasopharyngeal carcinoma treated
with radiotherapy and concurrent chemotherapy. Hum Pathol.
39:837–845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taheri M and Mahjoubi F: MRP1 but not MDR1
is associated with response to neoadjuvant chemotherapy in breast
cancer patients. Dis Markers. 34:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zöchbauer-Müller S, Filipits M, Rudas M,
Brunner R, Krajnik G, Suchomel R, Schmid K and Pirker R:
P-glycoprotein and MRP1 expression in axillary lymph node
metastases of breast cancer patients. Anticancer Res. 21(1A):
119–124. 2001.PubMed/NCBI
|
|
14
|
Kathawala RJ, Gupta P, Ashby CR Jr and
Chen ZS: The modulation of ABC transporter-mediated multidrug
resistance in cancer: A review of the past decade. Drug Resist
Updat. 18:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chatterjee K, Zhang J, Honbo N and
Karliner JS: Doxorubicin cardiomyopathy. Cardiology. 115:155–162.
2010. View Article : Google Scholar :
|
|
16
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: Protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View
Article : Google Scholar
|
|
18
|
Nath S, Daneshvar K, Roy LD, Grover P,
Kidiyoor A, Mosley L, Sahraei M and Mukherjee P: MUC1 induces drug
resistance in pancreatic cancer cells via upregulation of multidrug
resistance genes. Oncogenesis. 2:e512013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng M, Jing DD and Meng XJ: Effect of
MUC1 siRNA on drug resistance of gastric cancer cells to
trastuzumab. Asian Pac J Cancer Prev. 14:127–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang
L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1
carcinoma-associated protein confers resistance to genotoxic
anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Senduny FF, Badria FA, El-Waseef AM,
Chauhan SC and Halaweish F: Approach for chemosensitization of
cisplatin-resistant ovarian cancer by cucurbitacin B. Tumour Biol.
Aug 5–2015.(Epub ahead of print). PubMed/NCBI
|
|
22
|
Yiannakopoulou EC: Interaction of green
tea catechins with breast cancer endocrine treatment: A systematic
review. Pharmacology. 94:245–248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu H, Zhang XX, Wang YY and Chen SZ:
Honokiol inhibits arterial thrombosis through endothelial cell
protection and stimulation of prostacyclin. Acta Pharmacol Sin.
26:1063–1068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim BH and Cho JY: Anti-inflammatory
effect of honokiol is mediated by PI3K/Akt pathway suppression.
Acta Pharmacol Sin. 29:113–122. 2008. View Article : Google Scholar
|
|
25
|
Kumar A, Kumar Singh U and Chaudhary A:
Honokiol analogs: A novel class of anticancer agents targeting cell
signaling pathways and other bioactivities. Future Med Chem.
5:809–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arora S, Singh S, Piazza GA, Contreras CM,
Panyam J and Singh AP: Honokiol: A novel natural agent for cancer
prevention and therapy. Curr Mol Med. 12:1244–1252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee YJ, Lee YM, Lee CK, Jung JK, Han SB
and Hong JT: Therapeutic applications of compounds in the Magnolia
family. Pharmacol Ther. 130:157–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L, Waltenberger B, Pferschy-Wenzig
EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S,
Rollinger JM, Heiss EH, et al: Natural product agonists of
peroxisome proliferator-activated receptor gamma (PPARγ): A review.
Biochem Pharmacol. 92:73–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Munroe ME, Arbiser JL and Bishop GA:
Honokiol, a natural plant product, inhibits inflammatory signals
and alleviates inflammatory arthritis. J Immunol. 179:753–763.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chilampalli C, Zhang X, Kaushik RS, Young
A, Zeman D, Hildreth MB, Fahmy H and Dwivedi C: Chemopreventive
effects of combination of honokiol and magnolol with α-santalol on
skin cancer developments. Drug Discov Ther. 7:109–115.
2013.PubMed/NCBI
|
|
31
|
Shigemura K, Arbiser JL, Sun SY, Zayzafoon
M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE and Chung
LW: Honokiol, a natural plant product, inhibits the bone metastatic
growth of human prostate cancer cells. Cancer. 109:1279–1289. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ishitsuka K, Hideshima T, Hamasaki M, Raje
N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM,
Richardson P, et al: Honokiol overcomes conventional drug
resistance in human multiple myeloma by induction of
caspase-dependent and -independent apoptosis. Blood. 106:1794–1800.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Hu J, Chen LJ, Liu L, Chen X, Chen PL,
Yang G, Hou WL, Tang MH, Zhang F, Wang XH, et al: Liposomal
honokiol, a potent anti-angiogenesis agent, in combination with
radiotherapy produces a synergistic antitumor efficacy without
increasing toxicity. Exp Mol Med. 40:617–628. 2008. View Article : Google Scholar
|
|
35
|
Liu H, Zang C, Emde A, Planas-Silva MD,
Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K and Eucker J:
Anti-tumor effect of honokiol alone and in combination with other
anti-cancer agents in breast cancer. Eur J Pharmacol. 591:43–51.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park EJ, Min HY, Chung HJ, Hong JY, Kang
YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, et al:
Down-regulation of c-Src/EGFR-mediated signaling activation is
involved in the honokiol-induced cell cycle arrest and apoptosis in
MDA-MB-231 human breast cancer cells. Cancer Lett. 277:133–140.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hooijberg JH, Jansen G, Kathmann I,
Pieters R, Laan AC, van Zantwijk I, Kaspers GJ and Peters GJ:
Folates provoke cellular efflux and drug resistance of substrates
of the multidrug resistance protein 1 (MRP1). Cancer Chemother
Pharmacol. 73:911–917. 2014.PubMed/NCBI
|
|
38
|
Li Y, Liu D, Chen D, Kharbanda S and Kufe
D: Human DF3/MUC1 carcinoma-associated protein functions as an
oncogene. Oncogene. 22:6107–6110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schroeder JA, Masri AA, Adriance MC,
Tessier JC, Kotlarczyk KL, Thompson MC and Gendler SJ: MUC1
overexpression results in mammary gland tumorigenesis and prolonged
alveolar differentiation. Oncogene. 23:5739–5747. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Raina D, Kharbanda S and Kufe D: The MUC1
oncoprotein activates the anti-apoptotic phosphoinositide
3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol
Chem. 279:20607–20612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Siragusa M, Zerilli M, Iovino F,
Francipane MG, Lombardo Y, Ricci-Vitiani L, Di Gesù G, Todaro M, De
Maria R and Stassi G: MUC1 oncoprotein promotes refractoriness to
chemotherapy in thyroid cancer cells. Cancer Res. 67:5522–5530.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rivalland G, Loveland B and Mitchell P:
Update on Mucin-1 immunotherapy in cancer: A clinical perspective.
Expert Opin Biol Ther. 15:1773–1787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu D, Lu Q and Hu X: Down-regulation of
P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by
honokiol. Cancer Lett. 243:274–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang X, Beitler JJ, Wang H, Lee MJ, Huang
W, Koenig L, Nannapaneni S, Amin AR, Bonner M, Shin HJ, et al:
Honokiol enhances paclitaxel efficacy in multi-drug resistant human
cancer model through the induction of apoptosis. PLoS One.
9:e863692014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Arora S, Bhardwaj A, Srivastava SK, Singh
S, McClellan S, Wang B and Singh AP: Honokiol arrests cell cycle,
induces apoptosis, and potentiates the cytotoxic effect of
gemcitabine in human pancreatic cancer cells. PLoS One.
6:e215732011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leeman-Neill RJ, Cai Q, Joyce SC, Thomas
SM, Bhola NE, Neill DB, Arbiser JL and Grandis JR: Honokiol
inhibits epidermal growth factor receptor signaling and enhances
the antitumor effects of epidermal growth factor receptor
inhibitors. Clin Cancer Res. 16:2571–2579. 2010. View Article : Google Scholar : PubMed/NCBI
|
